Takahiro Koyanagi

7PUBLICATIONS
4CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersChemotherapyLiquid biopsiesMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Mar 01, 2026
Efficacy of lenvatinib plus pembrolizumab for recurrent endometrial cancer: a focus on the nonendometrioid histology including carcinosarcoma.

Yoshifumi Takahashi, Yuji Takei, Miku Takadera

|Apr 24, 2025
Progesterone Enhances Sensitivity of Ovarian Cancer Cells to SN38 Through Inhibition of Topoisomerase I and Inducing Ferroptosis.

Takahiro Koyanagi, Yasushi Saga, Yoshifumi Takahashi

|Dec 22, 2024
Forced Vasohibin-1 Expression Increases Paclitaxel Sensitivity of Ovarian Cancer by Inhibiting Microtubule Activity.

Takahiro Koyanagi, Yasushi Saga, Yoshifumi Takahashi

|Aug 29, 2024
Optimizing Timing of Intraperitoneal Chemotherapy to Enhance Intravenous Carboplatin Concentration.

Kohei Tamura, Natsuka Kimura, Hideyuki Ohzawa

|Aug 09, 2024
Cervical cancer screening efficacy using SurePath, ThinPrep and conventional cytology: A large data set analysis from the Japan Cancer Society.

Takahiro Koyanagi, Hiroyuki Fujiwara, Kouji Yamamoto

|Nov 28, 2023
The role of non-genomic actions of progesterone and its membrane receptor agonist in ovarian cancer cell death.

Takahiro Koyanagi, Yasushi Saga, Yoshifumi Takahashi

Pageof 2